secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001739410-25-000059
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%
--------------------------------------------------------------------

- Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.
- Cash, cash equivalents, and marketable securities $54.5M; runway into 1H 2027.
- RLYB212 program discontinued after Phase 2 PK data missed target concentrations.
- Workforce reduction of 40% (nine positions) with ~$1.7M in severance charges; substantially complete by end of Q2 2025.
- RLYB116 confirmatory PK/PD study on track to start in Q2 2025; Cohort 1 data in Q3, Cohort 2 in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/0001739410-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/rlyb-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001739410-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer